Other
Staphylococcus Aureus
3
Pipeline Programs↗
4
Active Trials↗
13
Companies Involved↗
Staphylococcus Aureus is an early-stage landscape with 3 programs across 13 companies. The most active players are AstraZeneca, Pfizer, Basilea Pharmaceutica. 2 therapies are approved.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical1
Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Analysis
Trial Status
48
clinical trials
Completed35 · 73%
Terminated6 · 13%
Recruiting4 · 8%
Unknown status2 · 4%
No longer available1 · 2%
Clinical Trials
Trial Activity
48 trials
Study of the Nasal Intracellular Reservoir of Staphylococcus Aureus in Patients With S. Aureus Bacteremia
Recruiting·—·N/A·NCT06594250·405 enrolled
Early Intravenous to Oral Antibiotic Switch in Uncomplicated Staphylococcus Aureus Bacteraemia
Recruiting·—·Phase 3·NCT06336824·290 enrolled
A Clinical Trial to Evaluate a Recombinant Staphylococcus Aureus Vaccine (Escherichia Coli) in Healthy Adults
Completed·Jiangsu Province Centers for Disease Control and Prevention·Phase 1·NCT02804711·144 enrolled
Treatment of Staphylococcus Aureus Colonization in Hand Eczema
Completed·—·N/A·NCT01591785·60 enrolled
A Clinical Trial to Evaluate a Recombinant Staphylococcus Aureus Vaccine (Escherichia Coli) in Healthy Adults
Completed·Jiangsu Province Centers for Disease Control and Prevention·Phase 1·NCT03966040·144 enrolled
Page 1 of 4
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)